other material
confidence high
sentiment positive
materiality 0.50
Ensyce raises $21M initial tranche of $43M Series C financing; Nasdaq compliance update
Ensysce Biosciences, Inc.
- Initial closing Aug 7, 2026 raised >$21M gross; issued 120,260 Series C preferred shares.
- Two-tranche $43M Securities Purchase Agreement; second tranche closes on clinical milestone.
- Company believes it satisfies Nasdaq's $2.5M minimum stockholders' equity (Rule 5550(b)(1)).
- Requested Aug 24, 2026 for second 180-day grace period on $1.00 bid price rule (equity >=$5M).